作者: Roos J. Jutten , John Harrison , Philippe R. Lee Meeuw Kjoe , Esther M. Opmeer , Niki S.M. Schoonenboom
DOI: 10.1016/J.DADM.2017.12.002
关键词:
摘要: Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed cognitive-functional composite (CFC). As a first validation step, investigated its test–retest reliability and feasibility use. Methods: We performed study with 2–3 weeks between assessments, including patients mild cognitive impairment (MCI) or AD dementia cognitively healthy participants. calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures compared baseline retest scores using paired-samples t-tests. evaluated by interviewing Results: Forty-three (40% female, mean age = 69.9) 30 controls (50% 65) were included. Subtest ranged from.70 to.96. found negligible improvements after retesting on only two subtests. Overall, perceived administration as feasible. Discussion: The is stable feasible measure MCI dementia, thereby meets important quality metrics clinically meaningful outcome measures.